近日，国内稀缺的专注于"血液流向管理"的平台型介入创新企业江苏臻亿医疗科技有限公司（以下简称"臻亿医疗"）宣布完成C轮数亿元融资。本轮融资 由东方富海、国元股权、厦门产投/创投、厦金创新、博正资本、思明科创等联合投资，老股东生命树资本继续加持。此次C轮融资是臻亿医疗在短短数年 内完成的多轮重要资本动作之一，资本持续追投，体现了市场对公司平台化布局、技术创新能力及商业化前景的高度认可，也标志着国产心血管介入企业 在高端器械领域的突破进入新阶段。 臻亿医疗成立于2019年，着重专注致死致残率极高且国内市场仍是空白的心血管疾病领域，以"臻于至善，亿万之重"为使命，迅速崛起成为中国高端医疗 器械行业中一股不可忽视的新兴力量。企业业务全面覆盖心脏瓣膜、外周、冠脉等多个介入治疗领域，是率先在全球范围内实现血液流向管理一站式创新 解决方案的平台化企业。成立至今，公司保持高速成长节奏，2023年完成B+轮融资后，公司研发、注册与临床推进全面加速。此次C轮融资的成功，为其 进入规模化商业阶段与国际化拓展阶段提供了坚实支撑。 中伦律师事务所为臻亿医疗本次融资提供了全流程法律服务，包括起草、修改交易文件，商务谈判，协助完成交割等法 ...

Core Viewpoint - Zhenyi Medical has successfully completed a C-round financing of several hundred million yuan, indicating strong market recognition of its platform layout, technological innovation, and commercialization prospects in the high-end medical device sector for cardiovascular interventions [2]. Industry Background: Accelerating Interventional Treatment for Structural Heart Disease - The aging population in China is leading to an increase in the incidence of valvular heart disease, heart failure, and peripheral vascular diseases, creating a demand for safer, minimally invasive interventional treatment options [3]. - Structural heart disease interventions, particularly transcatheter mitral and tricuspid valve repair and replacement, have become a significant innovation direction globally, yet the domestic market remains largely underdeveloped with low domestic replacement rates [3]. Company Positioning: Building a "Blood Flow Management" Platform - Founded in 2019, Zhenyi Medical focuses on high-mortality cardiovascular diseases where domestic products are lacking, covering four major disease areas: heart valves, heart failure, peripheral vascular, and coronary artery diseases [5]. - The company has maintained rapid growth and continuous financing, with the recent C-round financing supporting its transition to large-scale commercialization and international expansion [5]. Technology and Products: From "Single Point Breakthrough" to "Systematic Layout" - Zhenyi Medical's core competitiveness lies in its multi-technology product system, which includes valve repair, valve replacement, and vascular access interventions [6]. - The transcatheter mitral valve repair system (TEER) offers a minimally invasive treatment option for patients with moderate to severe mitral regurgitation, significantly reducing intraoperative risks and recovery times [8]. - The transcatheter mitral valve replacement system (TruDelta®) has entered the innovative medical device green channel of the National Medical Products Administration, marking a significant breakthrough in domestic transcatheter valve replacement technology [10]. - The company is also developing a tricuspid valve repair and replacement system, creating a dual-valve platform that addresses functional tricuspid regurgitation [13]. - Zhenyi Medical is constructing a comprehensive "full-channel" solution that includes peripheral vascular, coronary, and heart failure-related interventional devices, achieving systemic innovation in blood flow management [14]. Financing and Strategy: From Domestic Replacement to Global Layout - The recent financing round is seen as a milestone for Zhenyi Medical, with plans to leverage funds to drive strategic initiatives [15]. - Investors express confidence in the company's technological leadership, complete product lineup, and commercialization capabilities, which are expected to establish a competitive barrier in the domestic structural heart disease market [16]. Conclusion: A "New Cycle" for Domestic Interventions - The completion of the C-round financing not only marks a critical point in Zhenyi Medical's development but also reflects the accelerating maturity of the domestic structural heart disease intervention market [17]. - The company is building a full-chain capability from technological innovation and clinical validation to commercialization, with several core products nearing registration and market launch, indicating a significant opportunity for domestic high-end interventional devices [17].

Core Insights - Jiangsu Zhenyi Medical Technology Co., Ltd. has completed a C-round financing of several hundred million yuan, focusing on "blood flow management" in the high-end medical device sector [2][3] - The financing was led by multiple institutions including Dongfang Fuhai, Guoyuan Equity, and others, indicating strong investor interest in innovative medical solutions [2] Company Overview - Zhenyi Medical is recognized as an innovative high-end medical device company, focusing on high mortality and disability rate diseases that remain unaddressed in the domestic market [2] - The company has a comprehensive business coverage across four major disease areas: heart valve, heart failure, peripheral, and coronary artery diseases, making it the first domestic company to fully engage in these critical sectors [2] Innovation and Product Development - The company has applied for over 160 patents, with 80% being invention patents and more than 40 PCT international patents, showcasing its commitment to innovation [2] - Currently, over 15 projects are under research, with four key products—mitral valve repair, tricuspid valve repair, mitral valve replacement, and shockwave balloon—rapidly advancing through clinical registration [2] - These products have received widespread recognition from patients, clinical doctors, and industry peers, positioning Zhenyi Medical as a leader in the domestic market [2] Strategic Expansion Plans - The chairman of Zhenyi Medical emphasized the need for a nationwide base network to support the launch of multiple innovative products and accelerate product development [3] - The company plans to establish a high-end production cluster in the Yangtze River Delta, with a focus on R&D in Shanghai, and aims to create research and production centers in key regions [3] - Zhenyi Medical intends to leverage domestic clinical resources to build specialized education and operation centers, exploring new paths for international medical cooperation and advancing its global strategy [3]